# EDGAR Filing Document

**Accession Number:** 0001969581
**File Stem:** 0000914190-26-000067
**Filing Date:** 2026-4
**Character Count:** 11037
**Document Hash:** 0ee42ccad397465d267e7c8d44f55c11
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000067.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0000914190-26-000067

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260403

**FILED AS OF DATE**: 20260407

**DATE AS OF CHANGE**: 20260407

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bohnen Shane
- **CENTRAL INDEX KEY:** 0001969581

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 26845590

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

## Ex-24

```

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints James Hippel,
Anna Weispfenning, Melodie R. Rose, Andrew Nick, Sara Tucher,
or either of them acting alone, the undersigned's true and
lawful attorneys-in-fact and agent with full power of substitution
and resubstitution, for the undersigned and in the undersigned's name,
place and stead, in any and all capacities, to sign any or all Forms
3, Forms 4 and Forms 5 relating to beneficial ownership of securities
of Bio-Techne Corporation (the "Issuer"), to file the same, with all
exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission and to deliver a copy of the
same to the Issuer, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and
thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as the undersigned might or
could do in person, hereby ratifying and confirming all said
attorneys-in-fact and agent, or his substitute or substitutes, may
lawfully do or cause to be done by virtue thereof. The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such
capacity at the request of the undersigned, is not assuming any of
the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the
undersigned is no longer subject to the provisions of Section 16 of
the Securities Exchange Act of 1934 with respect to securities of
the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 4th day of April, 2023.

/s/ Shane Bohnen

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bohnen Shane<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP - General Counsel_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-04-03 |  | M |  | 2259 | A | $0 | 6644 | D |  |
| Common Stock | 2026-04-03 |  | F |  | 740 | D | $53.13 | 5904 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $47.60 |  |  |  |  |  |  | <sup>(1)</sup> | 2026-08-07 | Common Stock | 8848 |  | 8848 | D |  |
| Stock Option (Right to Buy) | $66.97 |  |  |  |  |  |  | <sup>(1)</sup> | 2027-08-05 | Common Stock | 8944 |  | 8944 | D |  |
| Stock Option (Right to Buy) | $120.46 |  |  |  |  |  |  | <sup>(1)</sup> | 2028-08-06 | Common Stock | 3460 |  | 3460 | D |  |
| Stock Option (Right to Buy) | $94.52 |  |  |  |  |  |  | <sup>(2)</sup> | 2029-08-15 | Common Stock | 3508 |  | 3508 | D |  |
| Stock Option (Right to Buy) | $73.76 |  |  |  |  |  |  | <sup>(3)</sup> | 2030-04-03 | Common Stock | 3928 |  | 3928 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2026-04-03 |  | M |  |  | 2259 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 2259 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $84.61 |  |  |  |  |  |  | <sup>(6)</sup> | 2030-08-15 | Common Stock | 16302 |  | 16302 | D |  |
| Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 49 |  | 49 | D |  |
| Performance Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 4802 |  | 4802 | D |  |
| Performance Stock Option (Right to Buy) | $84.61 |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 12924 |  | 12924 | D |  |
| Performance Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 10012 |  | 10012 | D |  |
| Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 3338 |  | 3338 | D |  |
| Stock Option (Right to Buy) | $74.91 |  |  |  |  |  |  | <sup>(11)</sup> | 2034-08-15 | Common Stock | 13488 |  | 13488 | D |  |
| Performance Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 13992 |  | 13992 | D |  |
| Restricted Stock Units | <sup>(4)</sup> |  |  |  |  |  |  | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 6996 |  | 6996 | D |  |
| Stock Option (Right to Buy) | $53.60 |  |  |  |  |  |  | <sup>(14)</sup> | 2035-08-15 | Common Stock | 17897 |  | 17897 | D |  |

---

### Footnotes:

(1) Fully exercisable.

(2) Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.

(3) Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.

(4) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(5) 2,259 restricted stock units vest on 4/3/2026.

(6) Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.

(7) 49 restricted stock units vest on 8/15/2026.

(8) Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(9) Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(10) 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.

(11) Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

(12) Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(13) 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

(14) Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.

**Signature:** /s/ Shane Bohnen  
**Date:** 2026-04-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**